Subscribe to our Email Alerts
Menu
Home
About Us
Company Overview
Company Values
Board of Directors
Executive Management
Corporate Directory
Products
DAYBUE™ (trofinetide)
Pipeline
Pipeline
Trofinetide
Rett Syndrome
NNZ-2591
Phelan-McDermid Syndrome
Angelman Syndrome
Pitt Hopkins Syndrome
Hypoxic-ischemic encephalopathy
Prader-Willi Syndrome
Science
Science Behind Neuren's Products
Trofinetide Published Studies & Presentations
Rett Syndrome
NNZ-2591Published Studies & Presentations
Phelan-McDermid Syndrome
Pitt Hopkins Syndrome
Angelman Syndrome
Investors
Investor Dashboard
Share Price Information
ASX Announcements
Annual and Interim Reports
Investor Presentations
Corporate Governance
Analyst Coverage
Shareholder Services
News & Media
Media
Contact
Contact Us
Email Alerts
Science
Home
>
Science
>
NNZ-2591Published Studies & Presentations
>
Phelan-McDermid Syndrome
Science Behind Neuren's Products
Trofinetide Published Studies & Presentations
Rett Syndrome
NNZ-2591Published Studies & Presentations
Phelan-McDermid Syndrome
Pitt Hopkins Syndrome
Angelman Syndrome
Phelan-McDermid Syndrome
26-Mar-2025
Safety, Efficacy, and Exposure‑Response of NNZ‑2591, a Synthetic Analog of Cyclic Glycine‑Proline (cGP), an IGF‑1 Metabolite, for the Treatment of Phelan‑McDermid Syndrome in Children and Adolescents
26-Mar-2025
The Evolving Genetic Landscape of Phelan-McDermid Syndrome and Implications for Diagnostics
11-Nov-2024
Improving Outcome Measures for Trials in Phelan-McDermid Syndrome (PMS): Development of PMS-Specific Clinician and Caregiver Impression-of-Change Measures
11-Nov-2024
NNZ-2591, A Novel IGF-1–Related Treatment for Neurodevelopmental Disorders, Demonstrates Efficacy for Children and Adolescents With Phelan-McDermid Syndrome
14-Oct-2024
Safety, Efficacy, and Exposure‑Response of NNZ‑2591, a Synthetic Analog of Cyclic Glycine‑Proline (cGP), an IGF‑1 Metabolite, for the Treatment of Phelan-McDermid Syndrome in Children and Adolescents
